IL218575A0 - Treatment of cancer - Google Patents
Treatment of cancerInfo
- Publication number
- IL218575A0 IL218575A0 IL218575A IL21857512A IL218575A0 IL 218575 A0 IL218575 A0 IL 218575A0 IL 218575 A IL218575 A IL 218575A IL 21857512 A IL21857512 A IL 21857512A IL 218575 A0 IL218575 A0 IL 218575A0
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24275209P | 2009-09-15 | 2009-09-15 | |
| US31703910P | 2010-03-24 | 2010-03-24 | |
| US33215010P | 2010-05-06 | 2010-05-06 | |
| US38185110P | 2010-09-10 | 2010-09-10 | |
| PCT/US2010/048973 WO2011034954A1 (en) | 2009-09-15 | 2010-09-15 | Treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL218575A0 true IL218575A0 (en) | 2012-05-31 |
Family
ID=43758997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL218575A IL218575A0 (en) | 2009-09-15 | 2012-03-11 | Treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20110160159A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2477985B1 (cg-RX-API-DMAC7.html) |
| JP (6) | JP5855568B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102666533A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010295646B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012005594A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2774015A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201200486A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL218575A0 (cg-RX-API-DMAC7.html) |
| MX (2) | MX342709B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011034954A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9770517B2 (en) | 2002-03-01 | 2017-09-26 | Immunomedics, Inc. | Anti-Trop-2 antibody-drug conjugates and uses thereof |
| PT2277551E (pt) | 2002-09-06 | 2013-08-22 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
| US10058621B2 (en) | 2015-06-25 | 2018-08-28 | Immunomedics, Inc. | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers |
| US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
| WO2011051894A1 (en) | 2009-10-29 | 2011-05-05 | Aventis Pharma S.A. | Novel antitumoral use of cabazitaxel |
| US20120064107A1 (en) * | 2010-05-18 | 2012-03-15 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other disease |
| EP2809686A4 (en) * | 2012-01-31 | 2015-11-25 | Cerulean Pharma Inc | POLYMERS ON CYCLODEXTRINBASIS FOR THERAPEUTIC ADMINISTRATION |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| US20140094432A1 (en) | 2012-10-02 | 2014-04-03 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| WO2014055913A1 (en) * | 2012-10-05 | 2014-04-10 | Cerulean Pharma Inc. | Treatment of cancer |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| US12310958B2 (en) | 2012-12-13 | 2025-05-27 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10413539B2 (en) | 2012-12-13 | 2019-09-17 | Immunomedics, Inc. | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) |
| US10206918B2 (en) | 2012-12-13 | 2019-02-19 | Immunomedics, Inc. | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers |
| US20240148873A1 (en) | 2012-12-13 | 2024-05-09 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| CN104837508A (zh) | 2012-12-13 | 2015-08-12 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
| US10137196B2 (en) | 2012-12-13 | 2018-11-27 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| US9492566B2 (en) | 2012-12-13 | 2016-11-15 | Immunomedics, Inc. | Antibody-drug conjugates and uses thereof |
| US10744129B2 (en) | 2012-12-13 | 2020-08-18 | Immunomedics, Inc. | Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2 |
| WO2014128108A1 (de) | 2013-02-21 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Estra-1,3,5(10),16-tetraen-3-carboxamide zur inhibierung von 17.beta.-hydroxysteroid dehdrogenase (akr1 c3) |
| EP2801370A1 (en) * | 2013-05-07 | 2014-11-12 | Fundació Privada Institut d'Investigació Oncològica de Vall Hebron | Methods and compositions for the treatment of cancer |
| US11253606B2 (en) | 2013-07-23 | 2022-02-22 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| EP3049078B1 (en) * | 2013-09-27 | 2018-06-27 | BlueLink Pharmaceuticals, Inc. | Treatment of cancer |
| BR112016016932A8 (pt) * | 2014-01-24 | 2020-06-16 | Sirtex Medical Ltd | uso de uma combinação de oxaliplatina (oxa), leucovorina (lv) e 5-fluorouracil (5-fu) |
| NZ734256A (en) * | 2015-02-12 | 2019-02-22 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| CA2981543A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| US10195175B2 (en) | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| CN108026075B (zh) | 2015-07-13 | 2021-06-29 | 大连万春布林医药有限公司 | 普那布林组合物 |
| SG10201913073YA (en) | 2015-08-20 | 2020-03-30 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
| FR3040860B1 (fr) * | 2015-09-10 | 2020-05-15 | Universite de Bordeaux | Milieu de conservation injectable pour la conservation de cellules du sang placentaire, de la moelle osseuse et du sang peripherique |
| US20190133963A1 (en) * | 2015-11-03 | 2019-05-09 | Nanoproteagen | Polymeric nanoparticles |
| RU2753543C1 (ru) | 2016-02-08 | 2021-08-17 | Бейондспринг Фармасьютикалс, Инк. | Композиции, содержащие тукаресол или его аналоги |
| CN108601841A (zh) | 2016-02-10 | 2018-09-28 | 免疫医疗公司 | Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性 |
| WO2017177055A1 (en) * | 2016-04-08 | 2017-10-12 | Liang Zhao | Cyclodextrin-based polymers for therapeutic delivery |
| CN109310385A (zh) | 2016-04-27 | 2019-02-05 | 免疫医疗公司 | 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效 |
| EP3463337A4 (en) | 2016-06-06 | 2020-02-12 | Beyondspring Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA |
| WO2018102769A1 (en) * | 2016-12-01 | 2018-06-07 | Bluelink Pharmaceuticals, Inc. | Treatment of cancer |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| SG11201907023UA (en) | 2017-02-01 | 2019-08-27 | Beyondspring Pharmaceuticals Inc | Method of reducing neutropenia |
| CA3050332A1 (en) | 2017-03-27 | 2018-10-04 | Immunomedics, Inc. | Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| BR112020014960A2 (pt) | 2018-01-24 | 2020-12-22 | Beyondspring Pharmaceuticals, Inc. | Composição e método para redução de trombocitopenia |
| WO2019232257A1 (en) * | 2018-06-01 | 2019-12-05 | Beyondspring Pharmaceuticals, Inc. | Composition and method of treating cancer associated with egfr mutation |
| CN113164600A (zh) | 2018-10-17 | 2021-07-23 | 百欧林纳克斯有限公司 | 转移性胰脏腺癌的治疗 |
| US20220072087A1 (en) | 2019-01-17 | 2022-03-10 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020148744A1 (en) | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| WO2021119464A1 (en) * | 2019-12-13 | 2021-06-17 | Veri Nano Inc. | Compositions and modular nano- and microparticles for the delivery of various agents and use thereof |
| JP2023511184A (ja) * | 2020-01-22 | 2023-03-16 | メドイミューン・リミテッド | 化合物及びその複合体 |
| CN117098531A (zh) * | 2021-01-08 | 2023-11-21 | 斯塔顿治疗公司 | 用于肠胃外使用的免疫调节酰亚胺化合物的稳定溶液 |
| CN114904013A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 硫酸乙酰肝素-骨化三醇偶联物，包含其的乙酰肝素酶响应性纳米粒，其制备方法及用途 |
| CN115109258A (zh) * | 2021-03-19 | 2022-09-27 | 江西中医药大学 | 7-乙基-10-羟基喜树碱聚合物、制备方法及其应用 |
| JP2024513505A (ja) | 2021-04-09 | 2024-03-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍を治療するための組成物及び方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| ES2058081T3 (es) | 1986-09-05 | 1994-11-01 | American Cyanamid Co | Poliesteres que contienen bloques de oxido de alquileno como sistemas de administracion de medicamentos. |
| JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| FR2665169A1 (fr) | 1990-07-30 | 1992-01-31 | Rhone Poulenc Chimie | Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres. |
| US5330768A (en) | 1991-07-05 | 1994-07-19 | Massachusetts Institute Of Technology | Controlled drug delivery using polymer/pluronic blends |
| GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US5990237A (en) * | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
| AU756796B2 (en) * | 1998-10-16 | 2003-01-23 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Combination therapy with VIP antagonist |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| AUPP913999A0 (en) * | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| US6420378B1 (en) * | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| AU2003243561A1 (en) * | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| US20040047835A1 (en) * | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
| PT2277551E (pt) * | 2002-09-06 | 2013-08-22 | Cerulean Pharma Inc | Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente |
| AU2003299651A1 (en) * | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7358262B2 (en) * | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
| CN1216057C (zh) * | 2003-03-28 | 2005-08-24 | 贵州省生物研究所 | 喜树碱类似物的衍生物及其制备方法 |
| CA2547934C (en) * | 2004-02-19 | 2013-05-21 | Abbott Laboratories | Methods of using gamma cyclodextrin to control blood glucose and insulin secretion |
| CA2569520C (en) * | 2004-06-04 | 2023-03-14 | Genentech, Inc. | Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab |
| TW200640493A (en) * | 2005-02-16 | 2006-12-01 | Insert Therapeutics Inc | Cyclodextrin-based polymers for therapeutics delivery |
| EP1913157B2 (en) * | 2005-06-28 | 2016-10-26 | Genentech, Inc. | Egfr and kras mutations for prediction of patient response to egfr inhibitor treatment |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| KR100917809B1 (ko) * | 2006-05-22 | 2009-09-18 | 에스케이케미칼주식회사 | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| WO2008148080A2 (en) * | 2007-05-24 | 2008-12-04 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin] |
| US20100056555A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
| EA201171195A8 (ru) * | 2009-03-30 | 2014-08-29 | Серулин Фарма Инк. | Конъюгаты, частицы, композиции "полимер-агент" и способы их применения |
| US20120114658A1 (en) * | 2009-09-15 | 2012-05-10 | John Ryan | Treatment of cancer |
-
2010
- 2010-09-15 CA CA2774015A patent/CA2774015A1/en not_active Abandoned
- 2010-09-15 CN CN2010800410580A patent/CN102666533A/zh active Pending
- 2010-09-15 AU AU2010295646A patent/AU2010295646B2/en not_active Ceased
- 2010-09-15 US US12/883,084 patent/US20110160159A1/en not_active Abandoned
- 2010-09-15 CA CA2939165A patent/CA2939165A1/en not_active Abandoned
- 2010-09-15 WO PCT/US2010/048973 patent/WO2011034954A1/en not_active Ceased
- 2010-09-15 JP JP2012529881A patent/JP5855568B2/ja not_active Expired - Fee Related
- 2010-09-15 MX MX2012003046A patent/MX342709B/es active IP Right Grant
- 2010-09-15 MX MX2016013249A patent/MX366955B/es unknown
- 2010-09-15 BR BR112012005594A patent/BR112012005594A2/pt not_active Application Discontinuation
- 2010-09-15 EA EA201200486A patent/EA201200486A1/ru unknown
- 2010-09-15 EP EP10817784.1A patent/EP2477985B1/en active Active
-
2012
- 2012-03-11 IL IL218575A patent/IL218575A0/en unknown
-
2013
- 2013-01-10 US US13/738,630 patent/US20130338103A1/en not_active Abandoned
- 2013-02-15 US US13/769,046 patent/US20130164282A1/en not_active Abandoned
-
2014
- 2014-11-04 JP JP2014223985A patent/JP2015025020A/ja not_active Withdrawn
-
2015
- 2015-04-01 US US14/675,815 patent/US20160058875A1/en not_active Abandoned
-
2016
- 2016-03-09 JP JP2016045695A patent/JP2016106143A/ja active Pending
-
2017
- 2017-04-26 US US15/498,056 patent/US20180071404A1/en not_active Abandoned
- 2017-10-10 JP JP2017196769A patent/JP2017226708A/ja not_active Withdrawn
-
2020
- 2020-06-25 JP JP2020109574A patent/JP2020164547A/ja active Pending
-
2022
- 2022-08-29 JP JP2022135758A patent/JP2022166327A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP5855568B2 (ja) | 2016-02-09 |
| CA2774015A1 (en) | 2011-03-24 |
| US20180071404A1 (en) | 2018-03-15 |
| JP2017226708A (ja) | 2017-12-28 |
| BR112012005594A2 (pt) | 2015-09-08 |
| MX2012003046A (es) | 2012-09-07 |
| CN102666533A (zh) | 2012-09-12 |
| CA2939165A1 (en) | 2011-03-24 |
| MX342709B (es) | 2016-10-10 |
| JP2022166327A (ja) | 2022-11-01 |
| US20110160159A1 (en) | 2011-06-30 |
| US20160058875A1 (en) | 2016-03-03 |
| JP2020164547A (ja) | 2020-10-08 |
| MX366955B (es) | 2019-07-31 |
| US20130338103A1 (en) | 2013-12-19 |
| WO2011034954A1 (en) | 2011-03-24 |
| JP2013504630A (ja) | 2013-02-07 |
| JP2015025020A (ja) | 2015-02-05 |
| US20130164282A1 (en) | 2013-06-27 |
| JP2016106143A (ja) | 2016-06-16 |
| AU2010295646B2 (en) | 2016-02-11 |
| EP2477985A4 (en) | 2013-05-15 |
| EA201200486A1 (ru) | 2012-08-30 |
| AU2010295646A1 (en) | 2012-04-05 |
| EP2477985A1 (en) | 2012-07-25 |
| EP2477985B1 (en) | 2018-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276362A (en) | Cancer treatment methods | |
| IL218575A0 (en) | Treatment of cancer | |
| IL217291A0 (en) | Exosome based treatment of cancer | |
| SG10201508495VA (en) | Combination treatment of cancer | |
| IL219073A (en) | A drug combination for cancer treatment | |
| EP2461814A4 (en) | PROSTATE CANCER TREATMENT | |
| ZA201300218B (en) | Treatment of blood cancer | |
| GB0915515D0 (en) | Treatment of vasculoproliferative conditions | |
| IL213761A0 (en) | Novel ortho-aminoamides for the treatment of cancer | |
| ZA201304226B (en) | Methods of treating cancer | |
| IL206491A0 (en) | Treatment of produce | |
| IL222958A0 (en) | Cancer treatment | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| EP2640390A4 (en) | METHODS OF TREATING CANCER | |
| GB0901456D0 (en) | Treatment of psoriasis | |
| IL215037A0 (en) | Treatment of pancreatic cancer | |
| ZA201202213B (en) | Treatment of minerals | |
| IL218230A0 (en) | Method of treating cancer | |
| IL200753A0 (en) | Treatment of psoriasis | |
| PL388252A1 (pl) | Terapia skojarzona raka jelita grubego | |
| GB0916686D0 (en) | Treatment of cancer | |
| GB0921757D0 (en) | Treatment of cancer | |
| GB201017356D0 (en) | Combination treatment of cancer | |
| GB201017354D0 (en) | Treatment of cancer | |
| AU2009900764A0 (en) | Treatment of cancer |